IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer
Olga Blomberg, Lorenzo Spagnuolo, Hannah Garner, Leonie Voorwerk, Olga I. Isaeva, Ewald van Dyk, Noor A. M. Bakker, Myriam Chalabi, Chris Klaver, Maxime Duijst, Kelly Kersten, Marieke Brüggemann, Dorien Pastoors, Cheei‐Sing Hau, Kim Vrijland, Elisabeth A.M. Raeven, Daphne Kaldenbach, Kevin Kos, Inna S. Afonina, Paulien Kaptein, Louisa R. Hoes, Willemijn S.M.E. Theelen, Paul Baas, Emile E. Voest, Rudi Beyaert, Daniela S. Thommen, Lodewyk F.A. Wessels, Karin E. de Visser, Marleen Kok
Abstract
Immune checkpoint blockade (ICB) has heralded a new era in cancer therapy. Research into the mechanisms underlying response to ICB has predominantly focused on T cells; however, effective immune responses require tightly regulated crosstalk between innate and adaptive immune cells. Here, we combine unbiased analysis of blood and tumors from metastatic breast cancer patients treated with ICB with mechanistic studies in mouse models of breast cancer. We observe an increase in systemic and intratumoral eosinophils in patients and mice responding to ICB treatment. Mechanistically, ICB increased IL-5 production by CD4 + T cells, stimulating elevated eosinophil production from the bone marrow, leading to systemic eosinophil expansion. Additional induction of IL-33 by ICB-cisplatin combination or recombinant IL-33 promotes intratumoral eosinophil infiltration and eosinophil-dependent CD8 + T cell activation to enhance ICB response. This work demonstrates the critical role of eosinophils in ICB response and provides proof-of-principle for eosinophil engagement to enhance ICB efficacy.